Pre-made Vofatamab benchmark antibody ( Whole mAb, anti-FGFR3 therapeutic antibody, Anti-ACH/CEK2/JTK4/CD333/HSFGFR3EX Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Vofatamab biosimilar, Whole mAb, Anti-FGFR3 Antibody: Anti-ACH/CEK2/JTK4/CD333/HSFGFR3EX therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vofatamab (B-701, Rainier Therapeutics) is an antibody that targets fibroblast growth factor receptor 3 (FGFR3), an established driver of bladder cancer and other malignancies.
| Products Name (INN Index) | Pre-Made Vofatamab biosimilar, Whole mAb, Anti-FGFR3 Antibody: Anti-ACH/CEK2/JTK4/CD333/HSFGFR3EX therapeutic antibody |
|---|---|
| INN Name | Vofatamab |
| Target | FGFR3 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 4wv1:BA:ED/3grw:HL |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | BioClin Therapeutics,Rainier Therapeutics |
| Conditions Approved | NA |
| Conditions Active | Urogenital cancer |
| Conditions Discontinued | Multiple myeloma,Solid tumours,Achondroplasia |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FGFR3 |
| Package |
